A Guide for Reviewing Submitted Manuscripts: (And Indications for the Design of Translational Research Studies on Biomarkers)

American Society of Clinical Oncology (ASCO). Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996; 14: 2843–77.

American Society of Clinical Oncology (ASCO). 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1998; 16: 793–5.

American Society of Clinical Oncology (ASCO). 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999; 17: 1080–2.

Hayes D.F. , Bast R.C. , Desch C.E. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996; 88: 1456–66.

Altman D.G. , De Stavola B.L. , Lowe S.B. , Stepniewska K.A. A review of survival analysis published in cancer journals. Br J Cancer 1995; 72: 515–8.

Altman D.G. , Lausen B. , Sauerbrei W. , Schumaker M. Danger of using “optimal” cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86: 829–35.

Biganzoli E. , Boracchi P. , Daidone M.G. , Gion M. , Marubini E. Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers. Int J Biol Markers 1999; 13: 107–23.

Altman D.G. Suboptimal analysis using ‘optimal’ cutpoints. Br J Cancer 1998; 78: 556–7.

Canadian Task Force on the Periodic Health Examination. The periodic health examination. Can Med Ass J 1979; 121: 1193–254.